These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17276756)

  • 1. Haemoglobin targets: we were wrong, time to move on.
    Strippoli GF; Tognoni G; Navaneethan SD; Nicolucci A; Craig JC
    Lancet; 2007 Feb; 369(9559):346-50. PubMed ID: 17276756
    [No Abstract]   [Full Text] [Related]  

  • 2. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
    Phrommintikul A; Haas SJ; Elsik M; Krum H
    Lancet; 2007 Feb; 369(9559):381-8. PubMed ID: 17276778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 4. Haemoglobin concentrations in chronic kidney disease.
    Fernandes M; Sawa H; Bellini G
    Lancet; 2007 Feb; 369(9559):365. PubMed ID: 17276763
    [No Abstract]   [Full Text] [Related]  

  • 5. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 7. Target haemoglobin concentrations in chronic kidney disease.
    Reinhold SW; Krämer BK; Banas B
    Lancet; 2007 May; 369(9572):1517. PubMed ID: 17482980
    [No Abstract]   [Full Text] [Related]  

  • 8. Anemia: To TREAT or not to TREAT--that is the question.
    Wiecek A
    Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.
    Macdougall IC; Hutton RD; Cavill I; Coles GA; Williams JD
    BMJ; 1990 Mar; 300(6725):655-9. PubMed ID: 2322705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of recombinant erythropoietin in the treatment of anemia of chronic renal insufficiency].
    Drüeke T; Zins B; Bererhi L; Casadevall N; Varet B
    Presse Med; 1989 Jun; 18(25):1235-7. PubMed ID: 2525772
    [No Abstract]   [Full Text] [Related]  

  • 12. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 13. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal erythropoietin treatment of children with chronic renal failure.
    Steele BT; Vigneux A
    Pediatr Nephrol; 1995 Jun; 9(3):359-60. PubMed ID: 7632534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The target hemoglobin in patients with chronic kidney disease.
    Singh AK
    Nephrol News Issues; 2006 Dec; 20(13):29-30. PubMed ID: 17168056
    [No Abstract]   [Full Text] [Related]  

  • 16. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European best practice guidelines 17-18: adverse effects.
    Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Carveth BG; Thompson K
    Nephrol Dial Transplant; 2000; 15 Suppl 4():51-6. PubMed ID: 11052149
    [No Abstract]   [Full Text] [Related]  

  • 19. Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
    Hayes C; Alam A; Black-Peart J; McFarlane SI
    Curr Diab Rep; 2010 Apr; 10(2):87-9. PubMed ID: 20425565
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.